Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98

Repligen Co. (NASDAQ:RGEN)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $160.98, but opened at $154.59. Repligen shares last traded at $156.00, with a volume of 183,643 shares.

Wall Street Analyst Weigh In

RGEN has been the topic of several recent analyst reports. KeyCorp upped their target price on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Stifel Nicolaus boosted their price target on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Trading Down 1.9 %

The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The company’s fifty day moving average is $190.02 and its 200-day moving average is $173.20. The firm has a market capitalization of $8.82 billion, a P/E ratio of 219.36, a P/E/G ratio of 5.38 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. Repligen’s quarterly revenue was down 16.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.68 EPS. As a group, sell-side analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last three months, insiders sold 25,597 shares of company stock valued at $5,039,532. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently made changes to their positions in RGEN. Fortis Capital Advisors LLC acquired a new position in shares of Repligen in the 4th quarter valued at $35,000. Park Place Capital Corp increased its position in shares of Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its position in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares in the last quarter. Signaturefd LLC increased its position in shares of Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares in the last quarter. Finally, Principal Securities Inc. acquired a new stake in shares of Repligen during the 4th quarter worth about $48,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.